In summary, these findings suggest that terazosin inhibits the MST1‐Foxo3a signalling pathway, thereby ameliorating hyperglycemia and obesity in NAFPD mice, and facilitating the restoration of pancreatic β‐cell function. The gene discussed is FOXO3; the disease is obesity due to melanocortin 4 receptor deficiency.